Concepts (223)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sepsis | 6 | 2023 | 296 | 0.860 |
Why?
|
| Shock, Septic | 4 | 2026 | 89 | 0.730 |
Why?
|
| Invasive Pulmonary Aspergillosis | 1 | 2021 | 5 | 0.690 |
Why?
|
| Toll-Like Receptor 4 | 3 | 2013 | 350 | 0.660 |
Why?
|
| Hypoxia | 3 | 2024 | 120 | 0.510 |
Why?
|
| Intensive Care Units | 7 | 2025 | 420 | 0.490 |
Why?
|
| Respiratory Insufficiency | 4 | 2024 | 154 | 0.480 |
Why?
|
| Oxazines | 2 | 2026 | 14 | 0.460 |
Why?
|
| Endotoxins | 2 | 2026 | 81 | 0.440 |
Why?
|
| Sugar Phosphates | 2 | 2013 | 3 | 0.440 |
Why?
|
| Disaccharides | 2 | 2013 | 11 | 0.440 |
Why?
|
| Pyridines | 2 | 2026 | 119 | 0.430 |
Why?
|
| Hospital Mortality | 5 | 2026 | 875 | 0.430 |
Why?
|
| Multiple Organ Failure | 3 | 2026 | 48 | 0.410 |
Why?
|
| Cannula | 2 | 2024 | 23 | 0.370 |
Why?
|
| Respiration, Artificial | 6 | 2021 | 298 | 0.350 |
Why?
|
| Noninvasive Ventilation | 2 | 2024 | 68 | 0.350 |
Why?
|
| Lipid A | 1 | 2010 | 67 | 0.300 |
Why?
|
| Polymyxin B | 2 | 2026 | 11 | 0.290 |
Why?
|
| Integrins | 4 | 1997 | 109 | 0.290 |
Why?
|
| Double-Blind Method | 8 | 2024 | 739 | 0.280 |
Why?
|
| Bacterial Infections | 1 | 2010 | 150 | 0.280 |
Why?
|
| Lipopolysaccharides | 1 | 2011 | 624 | 0.270 |
Why?
|
| Morpholines | 2 | 2026 | 91 | 0.270 |
Why?
|
| Erythrocyte Transfusion | 2 | 2026 | 77 | 0.260 |
Why?
|
| Babesiosis | 1 | 2026 | 13 | 0.240 |
Why?
|
| Aged | 18 | 2026 | 14963 | 0.240 |
Why?
|
| Mucoproteins | 2 | 1997 | 4 | 0.240 |
Why?
|
| Receptors, Lymphocyte Homing | 2 | 1997 | 15 | 0.240 |
Why?
|
| Immunoglobulins | 2 | 1997 | 74 | 0.230 |
Why?
|
| Middle Aged | 19 | 2026 | 18273 | 0.230 |
Why?
|
| Critical Care | 4 | 2017 | 402 | 0.220 |
Why?
|
| Adult | 19 | 2026 | 17358 | 0.220 |
Why?
|
| Humans | 33 | 2026 | 65141 | 0.220 |
Why?
|
| Male | 22 | 2026 | 31055 | 0.210 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2004 | 40 | 0.210 |
Why?
|
| Female | 23 | 2026 | 34030 | 0.210 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2004 | 38 | 0.210 |
Why?
|
| Guideline Adherence | 2 | 2021 | 307 | 0.200 |
Why?
|
| Clinical Trials as Topic | 3 | 2019 | 460 | 0.200 |
Why?
|
| Propensity Score | 1 | 2024 | 189 | 0.200 |
Why?
|
| Treatment Outcome | 8 | 2026 | 5790 | 0.190 |
Why?
|
| Severity of Illness Index | 6 | 2026 | 1559 | 0.170 |
Why?
|
| Ventilator-Induced Lung Injury | 1 | 2021 | 10 | 0.170 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 19 | 0.170 |
Why?
|
| Blood Gas Analysis | 2 | 2017 | 34 | 0.160 |
Why?
|
| Tidal Volume | 2 | 2019 | 41 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 1 | 2026 | 801 | 0.150 |
Why?
|
| Blood Substitutes | 1 | 2017 | 5 | 0.130 |
Why?
|
| Acute Chest Syndrome | 1 | 2017 | 5 | 0.130 |
Why?
|
| Integrin beta Chains | 1 | 1997 | 2 | 0.130 |
Why?
|
| Patient Safety | 1 | 2020 | 259 | 0.130 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2017 | 45 | 0.130 |
Why?
|
| Protein C | 2 | 2008 | 26 | 0.130 |
Why?
|
| Hemoglobins | 1 | 2017 | 136 | 0.120 |
Why?
|
| Prospective Studies | 4 | 2025 | 3310 | 0.120 |
Why?
|
| Thiamine Deficiency | 1 | 2016 | 8 | 0.120 |
Why?
|
| Thiamine | 1 | 2016 | 21 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 706 | 0.120 |
Why?
|
| Protein Structure, Tertiary | 1 | 1997 | 676 | 0.120 |
Why?
|
| Lactic Acid | 1 | 2016 | 75 | 0.110 |
Why?
|
| Aminopyridines | 2 | 2026 | 34 | 0.110 |
Why?
|
| APACHE | 3 | 2010 | 42 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2024 | 2619 | 0.110 |
Why?
|
| Shock | 1 | 2015 | 33 | 0.110 |
Why?
|
| Pyrimidines | 2 | 2026 | 145 | 0.110 |
Why?
|
| Fluid Therapy | 1 | 2015 | 46 | 0.110 |
Why?
|
| Bayes Theorem | 2 | 2026 | 125 | 0.110 |
Why?
|
| Emergency Service, Hospital | 2 | 2024 | 1149 | 0.100 |
Why?
|
| Lymphocytes | 1 | 1994 | 204 | 0.100 |
Why?
|
| Infusions, Intravenous | 2 | 2010 | 175 | 0.090 |
Why?
|
| Gram-Positive Bacteria | 1 | 2011 | 35 | 0.080 |
Why?
|
| Gram-Negative Bacteria | 1 | 2011 | 56 | 0.080 |
Why?
|
| Phospholipids | 1 | 2011 | 81 | 0.080 |
Why?
|
| United States | 5 | 2021 | 8098 | 0.080 |
Why?
|
| Organ Dysfunction Scores | 2 | 2025 | 23 | 0.080 |
Why?
|
| Acute Disease | 2 | 2024 | 663 | 0.080 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 40 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 2484 | 0.080 |
Why?
|
| Renal Dialysis | 1 | 2011 | 191 | 0.080 |
Why?
|
| Antibodies, Neutralizing | 1 | 2011 | 217 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 296 | 0.070 |
Why?
|
| Choriocarcinoma | 1 | 2008 | 3 | 0.070 |
Why?
|
| Critical Illness | 2 | 2010 | 330 | 0.070 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2008 | 11 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2010 | 576 | 0.070 |
Why?
|
| Uterine Neoplasms | 1 | 2008 | 36 | 0.070 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2008 | 67 | 0.070 |
Why?
|
| Hospitalization | 2 | 2026 | 1392 | 0.070 |
Why?
|
| Incidence | 2 | 2019 | 1419 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 856 | 0.070 |
Why?
|
| Biomarkers | 2 | 2026 | 1480 | 0.070 |
Why?
|
| Cell Adhesion Molecules | 3 | 1997 | 95 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2025 | 5614 | 0.060 |
Why?
|
| Leukocyte Count | 1 | 2026 | 101 | 0.060 |
Why?
|
| Parasitemia | 1 | 2026 | 49 | 0.060 |
Why?
|
| Blood Glucose | 1 | 2008 | 497 | 0.060 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2005 | 40 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2020 | 208 | 0.060 |
Why?
|
| Pyridazines | 1 | 2024 | 10 | 0.050 |
Why?
|
| Insulin | 1 | 2008 | 695 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 202 | 0.050 |
Why?
|
| Adaptive Clinical Trials as Topic | 1 | 2023 | 5 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2024 | 6865 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2008 | 525 | 0.050 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2024 | 61 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 197 | 0.050 |
Why?
|
| Pulmonary Circulation | 1 | 2003 | 27 | 0.050 |
Why?
|
| Neutrophils | 1 | 2026 | 390 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2017 | 1016 | 0.050 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2023 | 72 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2010 | 2102 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2004 | 380 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 3 | 1997 | 426 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2026 | 448 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2003 | 251 | 0.040 |
Why?
|
| Neuromuscular Blockade | 1 | 2021 | 10 | 0.040 |
Why?
|
| Early Medical Intervention | 1 | 2021 | 20 | 0.040 |
Why?
|
| Prone Position | 1 | 2021 | 28 | 0.040 |
Why?
|
| HIV Infections | 1 | 2008 | 955 | 0.040 |
Why?
|
| Vasodilator Agents | 1 | 2021 | 70 | 0.040 |
Why?
|
| Positive-Pressure Respiration | 1 | 2021 | 51 | 0.040 |
Why?
|
| Leukemia, Erythroblastic, Acute | 2 | 1997 | 7 | 0.040 |
Why?
|
| Patient Positioning | 1 | 2021 | 50 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2011 | 3149 | 0.040 |
Why?
|
| Heart | 1 | 2003 | 297 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2023 | 250 | 0.040 |
Why?
|
| Research Design | 1 | 2023 | 588 | 0.040 |
Why?
|
| Cell Adhesion | 3 | 1997 | 218 | 0.040 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2021 | 66 | 0.040 |
Why?
|
| Prognosis | 1 | 2004 | 1785 | 0.040 |
Why?
|
| HLA-DR Antigens | 1 | 2019 | 26 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2021 | 189 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 64 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 2 | 1997 | 500 | 0.040 |
Why?
|
| Intubation, Intratracheal | 1 | 2020 | 195 | 0.040 |
Why?
|
| Transfection | 2 | 1997 | 701 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2019 | 110 | 0.040 |
Why?
|
| Microvilli | 1 | 1997 | 6 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 2017 | 19 | 0.030 |
Why?
|
| Lung | 1 | 2003 | 964 | 0.030 |
Why?
|
| Methemoglobinemia | 1 | 2017 | 9 | 0.030 |
Why?
|
| Jehovah's Witnesses | 1 | 2017 | 19 | 0.030 |
Why?
|
| Placebos | 1 | 2017 | 73 | 0.030 |
Why?
|
| Treatment Refusal | 1 | 2017 | 58 | 0.030 |
Why?
|
| Epitope Mapping | 1 | 1997 | 52 | 0.030 |
Why?
|
| North America | 1 | 2017 | 114 | 0.030 |
Why?
|
| Cations | 1 | 1997 | 64 | 0.030 |
Why?
|
| Oximetry | 1 | 2017 | 49 | 0.030 |
Why?
|
| Pregnancy | 1 | 2004 | 2374 | 0.030 |
Why?
|
| Leukocytes | 1 | 1997 | 105 | 0.030 |
Why?
|
| Serine | 1 | 1997 | 90 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2021 | 528 | 0.030 |
Why?
|
| Cattle | 1 | 2017 | 320 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 736 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 844 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2019 | 587 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2017 | 195 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 1997 | 354 | 0.030 |
Why?
|
| Ligands | 1 | 1997 | 415 | 0.030 |
Why?
|
| Cross Infection | 1 | 2017 | 164 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 2 | 1997 | 875 | 0.030 |
Why?
|
| Central Venous Pressure | 1 | 2015 | 14 | 0.030 |
Why?
|
| Young Adult | 2 | 2017 | 4812 | 0.030 |
Why?
|
| Water-Electrolyte Balance | 1 | 2015 | 15 | 0.030 |
Why?
|
| Furosemide | 1 | 2015 | 19 | 0.030 |
Why?
|
| Diuretics | 1 | 2015 | 58 | 0.030 |
Why?
|
| Pneumonia | 1 | 2017 | 291 | 0.030 |
Why?
|
| Random Allocation | 1 | 2015 | 200 | 0.030 |
Why?
|
| Manganese | 1 | 1994 | 20 | 0.030 |
Why?
|
| Leukocyte Common Antigens | 1 | 1994 | 58 | 0.030 |
Why?
|
| Animals | 4 | 2017 | 21333 | 0.030 |
Why?
|
| Integrin beta1 | 1 | 1994 | 32 | 0.030 |
Why?
|
| Risk Factors | 1 | 2004 | 5430 | 0.030 |
Why?
|
| Polymers | 1 | 2017 | 332 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2015 | 137 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 1997 | 1979 | 0.030 |
Why?
|
| Cell Line | 2 | 1997 | 2023 | 0.030 |
Why?
|
| Rats | 1 | 1997 | 1994 | 0.030 |
Why?
|
| Protein Binding | 1 | 1997 | 1639 | 0.020 |
Why?
|
| Hypertension | 1 | 2017 | 612 | 0.020 |
Why?
|
| Mice | 2 | 1997 | 11114 | 0.020 |
Why?
|
| Intestines | 1 | 1993 | 178 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1993 | 241 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 415 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 1993 | 283 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1993 | 639 | 0.020 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2008 | 4 | 0.020 |
Why?
|
| Respiratory Dead Space | 1 | 2008 | 2 | 0.020 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2008 | 15 | 0.020 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2008 | 62 | 0.020 |
Why?
|
| Viral Load | 1 | 2008 | 230 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2008 | 323 | 0.020 |
Why?
|
| Point-of-Care Systems | 1 | 2008 | 126 | 0.020 |
Why?
|
| Recurrence | 1 | 2008 | 657 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2008 | 194 | 0.010 |
Why?
|
| Drug Costs | 1 | 2005 | 55 | 0.010 |
Why?
|
| Software | 1 | 2008 | 400 | 0.010 |
Why?
|
| Muscles | 1 | 1984 | 179 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 1698 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 710 | 0.010 |
Why?
|
| Vascular Capacitance | 1 | 2003 | 2 | 0.010 |
Why?
|
| Cardiac Volume | 1 | 2003 | 7 | 0.010 |
Why?
|
| Ventricular Function | 1 | 2003 | 22 | 0.010 |
Why?
|
| Ventricular Pressure | 1 | 2003 | 31 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 2003 | 47 | 0.010 |
Why?
|
| Patient Selection | 1 | 2005 | 485 | 0.010 |
Why?
|
| HIV-1 | 1 | 2008 | 706 | 0.010 |
Why?
|
| Diastole | 1 | 2003 | 90 | 0.010 |
Why?
|
| Adolescent | 1 | 2013 | 6306 | 0.010 |
Why?
|
| Microscopy, Immunoelectron | 1 | 1997 | 30 | 0.010 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 1997 | 14 | 0.010 |
Why?
|
| Macrophage-1 Antigen | 1 | 1997 | 29 | 0.010 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 1997 | 62 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1997 | 251 | 0.010 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 1993 | 15 | 0.010 |
Why?
|
| Fibronectins | 1 | 1993 | 44 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1993 | 2188 | 0.000 |
Why?
|
| Rhodamines | 1 | 1984 | 20 | 0.000 |
Why?
|
| Glycerol | 1 | 1984 | 34 | 0.000 |
Why?
|
| Muscle Relaxation | 1 | 1984 | 32 | 0.000 |
Why?
|
| Rabbits | 1 | 1984 | 338 | 0.000 |
Why?
|
| Models, Biological | 1 | 1984 | 1192 | 0.000 |
Why?
|